Clinical significance of assaying anti-MOG antibody in cerebrospinal fluid in MOG-antibody-associated diseases: A case report

Mult Scler Relat Disord. 2019 Feb:28:165-166. doi: 10.1016/j.msard.2018.12.035. Epub 2018 Dec 29.

Abstract

The serum diagnosis of anti-myelin oligodendrocyte glycoprotein antibody (MOG-Ab) associated diseases can be confirmed by the presence of the MOG-Ab, yet its levels in cerebrospinal fluid (CSF) are of unknown significance. We report the case of a 59-year-old woman with a history of 12 recurrent central nervous system lesions in the optic nerve, cerebrum, and spinal cord. The woman's condition improved by each steroid therapy. She tested seronegative for MOG-Ab, yet CSF-positive, leading to a diagnosis of MOG-Ab-associated encephalomyelitis. Our experience suggests measuring MOG-Ab in CSF and serum to prevent the underdiagnosis of MOG-Ab-associated diseases.

Keywords: Anti-MOG antibody; Cerebrospinal fluid; Encephalomyelitis; Myelin oligodendrocyte glycoprotein; Optic neuritis.

Publication types

  • Case Reports

MeSH terms

  • Autoantibodies / blood
  • Autoantibodies / cerebrospinal fluid*
  • Biomarkers / blood
  • Biomarkers / cerebrospinal fluid
  • Diagnosis, Differential
  • Encephalomyelitis / cerebrospinal fluid*
  • Encephalomyelitis / diagnostic imaging
  • Encephalomyelitis / drug therapy
  • Encephalomyelitis / immunology*
  • Female
  • Humans
  • Middle Aged
  • Myelin-Oligodendrocyte Glycoprotein / immunology*
  • Steroids / therapeutic use

Substances

  • Autoantibodies
  • Biomarkers
  • Myelin-Oligodendrocyte Glycoprotein
  • Steroids